CLAIMS

1. Use of an isolated blood preparation consisting of platelet- and lymphocyte-enriched plasma, comprising:

- platelets at a concentration ranging from 110 x 10^6/ml to 330 x 10^6/ml, preferably from 150x10^6/ml to 330 x 10^6/ml;
- white blood cells $CD45^+$, $CD31^+$ and $CD34^-$ at a concentration ranging from 0.1x10^6/ml to 2.0x10^6/ml, preferably from 0.1x10^6/ml to 0.7x10^6/ml;
- red blood cells at a concentration ranging from 0 to 0.03x10^9/ml, preferably less than 0.01x10^9/ml,

in the manufacture of medicament for wound healing, the regeneration of skin tissues, stimulating angiogenesis or the treatment of lesions of orthopedic or oncological origin such as bone and cartilage damages, post-surgery lesions or wounds; skin ulcers, decubitus sores, pressure ulcers, venous leg ulcers, arterial ulcers, diabetic foot ulcers, corneal lesions such as scarring of the cornea and corneal ulcers; periodontal tissue damages or periosteal lesions.

2. The use according to claim 1, wherein the white blood cells $CD45^+$, $CD31^+$ and $CD34^-$ comprise lymphocytes, monocytes and granulocytes.

3. The use according to claim 2, wherein lymphocytes range from 46.2% to 80.6%, preferably from 61.6% to 73.7% of total white blood cells $CD45^+$, $CD31^+$ and $CD34^-$.

4. The use according to claim 2 or 3, wherein lymphocytes comprise T cells, angiogenic T lymphocytes (Tang), B cells, NK cells and EPC cells.

5. The use according to claim 4, wherein T cells, angiogenic T lymphocytes (Tang), B cells, NK cells and EPC cells are in the following 25%-75% percentiles, as determined by flow cytometry analysis:

T cells	51.54-66.11
B cells	6.65-10.66
NKs	4.92-10.89

Tang (CD3+/184+/31+)	19.20-27.32
CD31+/146+/90+ (EPCs)	0.195-0.565

6. The use according to claim 2, wherein monocytes are $CD14^+$ and $CD16^+$ or $CD16^-$ and range from 7.7% to 40.0%, preferably from 15.9% to 23.1%, of total white blood cells $CD45^+$, $CD31^+$ and $CD34^-$

7. The use according to claim 6, wherein said monocytes are in the following 25%-75% percentiles, as determined by flow cytometry analysis:

Monocytes	6.44-13.02

8. The use according to claim 2, wherein granulocytes are $CD15^+/16^+$and they range from 3.3% to 32.9%, preferably from 5.9% to 16.7%, of total white blood cells $CD45^+$, $CD31^+$ and $CD34^-$.

9. The use according to claim 8, wherein granulocytes are in the following 25%-75% percentiles, as determined by flow cytometry analysis:

Granulocytes	2.87-10.87

10. A method for preparing a blood preparation, which comprises the following steps:

(i) centrifuging from 2 to 7ml of whole blood in a centrifugation tube at 293-660g, preferably at 458g, for 5 up to 10 min at room temperature, thereby obtaining the separation of an upper and lower phase, wherein the upper phase contains plasma enriched in platelets and lymphocytes and the lower phase contains red cells;

(ii) collecting the upper phase containing the plasma enriched in platelets and lymphocytes.

11. The method of claim 10, wherein said centrifugation tube comprises a rubber stopper (1); a membrane separating the tube in an upper and a lower volume (2), defining the corresponding upper and lower phases according to claim 10; a ring nut

placed at the bottom end (4) and operating an inner piston (3), which is allowed to move up and down the tube lower volume.

12. The method of claim 11, wherein the membrane consists of a hydrophobic disk barrier or membrane with 15 to 200 micron porosity and provided with a central hole of 1.5 to 2.5 mm diameter.

13. A blood preparation obtainable by the method of claims 10-12.

14. Use of the blood preparation according to claim 13 in the manufacture of a medicament for the treatment of lesions of orthopedic or oncological origin such as bone and cartilage damages, post-surgery lesions or wounds; skin ulcers, decubitus sores, pressure ulcers, venous leg ulcers, arterial ulcers, diabetic foot ulcers, corneal lesions such as scarring of the cornea and corneal ulcers; periodontal tissue damages or periosteal lesions.

15. The isolated blood preparation consisting of platelet- and lymphocyte-enriched plasma as defined in claim 13 when used in the following cosmetic treatments: anti-aging, scar repairing, wrinkle, acne, alopecia and burns.

16. A pharmaceutical or cosmetic composition containing the isolated blood preparation of claim 13.